Insights

More Articles Back to Article

FDA finds problems at Eli Lilly COVID-19 drug plant

FDA inspectors reportedly found serious quality control problems at Eli Lilly's plant in Branchburg, N.J., that's ramping up production of a COVID-19 antibody drug touted by President Donald Trump as a cure for the virus, according to federal documents and three sources with knowledge of the matter. Authorities discovered that data on the site's various manufacturing processes had been deleted and were not properly audited during a November inspection, according to government documents. Reuters (10/13)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!